Vraj Rangrej, Visiting medical student at NewYork-Presbyterian Hospital, shared a post on LinkedIn:
“Revolutionising Approaches to Lymphoma and CLL Therapies
“Richter Transformation in the Era of Targeted therapies” from leading expert Dr. Adam Kittai, MD of Icahn School of Medicine at Mount Sinai.
– Optimizing BTK and BCL2 inhibitors for high-risk disease
– Emerging CAR-T approaches
A huge shoutout to the incredible team.
Special Thanks to Dr. Adam Kittai.”